소아 당뇨병 치료 시장 규모, 점유율, 동향 분석 리포트 : 유형별, 치료법별, 투여 경로별, 유통경로별, 지역별, 부문별 예측(2024-2030년)

Pediatric Diabetes Therapeutic Market Size, Share & Trends Analysis Report By Type (Type 1, Type 2), By Treatment (Insulin, GLP-1, Biguanide, SGLT2), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,257,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,645,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,420,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

소아 당뇨병 치료 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 소아 당뇨병 치료 시장 규모는 2030년까지 221억 4,000만 달러에 달하며, 2024-2030년 CAGR은 13.9%로 성장할 것으로 예측됩니다.

이 시장을 주도하는 것은 주로 소아 당뇨병 유병률 증가와 조기 진단 및 효과적인 관리에 대한 관심이 증가하고 있기 때문입니다. 국제당뇨병연맹(IDF)은 2022년 전 세계 875만 명의 1형 당뇨병(T1D) 환자 중 20세 미만 환자는 152만 명에 달할 것으로 추산하고 있습니다. 이러한 급증은 유전적 소인, 환경적 요인, 생활패턴의 변화에 기인하는 바가 큽니다.

당뇨병 관리 분야의 기술 발전은 시장 성장에 긍정적인 영향을 미칠 것으로 예상됩니다. 지속형 혈당 측정기(CGM), 인슐린 펌프, 인공 췌장 시스템 등의 기술 혁신은 더 나은 혈당 조절을 가능하게 하고 합병증 위험을 줄일 수 있습니다. 예를 들어 미국 FDA는 2023년 6월, 10세 이상의 2형 당뇨병(T2D) 환아의 혈당 조절을 개선하기 위해 신잘디(메트포르민 염산염과 엠파글리플로진 복합제)와 자디앙스(엠파글리플로진)를 식이요법과 운동 요법을 보조하는 목적으로 승인했습니다. 승인했습니다. 이번 승인으로 소아 2형 당뇨병 환자들의 치료 옵션이 크게 확대되고, 임상 현장에서의 폭넓은 약물 도입이 촉진될 것으로 기대됩니다. 이번 승인은 젊은 환자들에게 효과적인 치료법에 대한 접근성을 확대하여 질병 관리와 장기적인 건강 결과를 개선하는 데 있으며, 중요한 발걸음을 내딛은 것입니다.

또한 소아 당뇨병에 대한 인식이 높아지고 조기 진단이 가능해지면서 인슐린 치료제, 비구아니드, GLP-1 수용체 작용제, SGLT2 억제제 등 다양한 치료 옵션에 대한 채택이 증가하고 있습니다. 또한 소아 당뇨병 치료 접근성을 개선하기 위한 정부의 지원적 노력과 정책도 시장을 촉진하고 있습니다. 전 세계 소아 인구는 지속적으로 증가하고 있으며, 당뇨병 유병률도 증가하고 있으며, 예측 기간 중 당뇨병 치료제에 대한 수요가 크게 증가할 것으로 예상됩니다.

소아당뇨병치료제 시장 보고서 하이라이트

• 제1형 부문은 2023년 79.32%의 가장 큰 매출 점유율을 차지할 것으로 예상됩니다. 이는 1형 질환의 발병률과 유병률 증가와 새로운 치료제에 대한 세계 수요 증가에 기인합니다.
• 치료제 부문에서는 인슐린 부문이 2023년 35.88%로 가장 큰 점유율을 차지할 것으로 예상됩니다. 이는 소아 환자에게 해를 끼치지 않고 안전하고 효과적으로 인슐린을 투여할 수 있는 새로운 전달 시스템의 개발 및 상용화에 기인합니다.
• 투여 경로별로는 비경구 부문이 2023년 시장에서 62.50%의 가장 큰 점유율을 차지할 것으로 예상됩니다. 이는 소아 당뇨병 환자 치료에 있으며, 새로운 피하 및 정맥 주사제가 승인되고 있기 때문으로 분석됩니다.
• 유통 경로에서 소매 약국 부문은 2023년 시장에서 47.49%의 가장 큰 점유율을 차지할 것으로 예상됩니다. 이는 당뇨병 치료를 위한 소아 환자의 처방전을 보충하기 위한 약물의 쉬운 접근성과 가용성과 같은 이점에 기인할 수 있습니다.
• 북미는 2023년 41.49%의 점유율을 차지하며 시장을 장악했습니다. 이는 높은 수준의 의료 인프라, 소아 당뇨병 유병률 증가, 임상시험 및 치료에 대한 유리한 규제 및 상환 등의 요인으로 인한 것입니다.

목차

제1장 조사 방법과 범위

제2장 개요

제3장 소아 당뇨병 치료 시장의 변수, 동향, 범위

• 시장 계통 전망
  • 모시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 소아 당뇨병 치료 시장 분석 툴
  • 업계 분석 - Porter의 산업 분석
  • PESTEL 분석
  • 파이프라인 분석

제4장 소아 당뇨병 치료제 시장 : 유형 추정·동향 분석

• 세계의 소아 당뇨병 치료제 시장 : 유형 대시보드
• 세계의 소아 당뇨병 치료제 시장 : 유형 변동 분석
• 유형별, 매출
• 유형 1
• 유형 2

제5장 소아 당뇨병 치료 시장 : 치료법 추정·동향 분석

• 세계의 소아 당뇨병 치료 시장 : 치료법 대시보드
• 세계의 소아 당뇨병 치료 시장 : 치료법 변동 분석
• 치료법별, 매출
• 인슐린
• GLP-1 수용체 작용제
• 비구아니드
• SGLT2 저해제
• 기타

제6장 소아 당뇨병 치료제 시장 : 투여 경로 추정·동향 분석

• 세계의 소아 당뇨병 치료제 시장 : 투여 경로 대시보드
• 세계의 소아 당뇨병 치료제 시장 : 투여 경로 변동 분석
• 투여 경로별, 매출
• 경구
• 비경구
• 기타

제7장 소아 당뇨병 치료제 시장 : 유통경로 추정·동향 분석

• 세계의 소아 당뇨병 치료제 시장 : 유통경로 대시보드
• 세계의 소아 당뇨병 치료제 시장 : 유통경로 변동 분석
• 유통경로별, 매출
• 병원 약국
• 소매 약국
• 온라인 약국

제8장 소아 당뇨병 치료제 시장 : 제품, 용도, 최종 용도, 지역별 추정·동향 분석

• 지역 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년 :
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제9장 경쟁 구도

• 주요 시장 참여 기업에 의한 최근 동향과 영향 분석
• 기업/경쟁의 분류
• 벤더 구도
  • Key company market share analysis, 2023
  • Boehringer Ingelheim International GmbH.
  • Eli Lilly and Company
  • Sanofi
  • Vertex Pharmaceuticals Incorporated
  • Novo Nordisk A/S
  • AstraZeneca.
  • MannKind Corporation
  • Xeris Pharmaceuticals
  • Amphastar Pharmaceuticals, Inc.

KSA

영문 목차

영문목차

Pediatric Diabetes Therapeutic Market Growth & Trends:

The global pediatric diabetes therapeutic market size is anticipated to reach USD 22.14 billion by 2030, growing at a CAGR of 13.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the rising prevalence of diabetes among children and the increasing focus on early diagnosis and effective management. The International Diabetes Federation (IDF) estimates that in 2022, out of the 8.75 million people living with type 1 diabetes (T1D) worldwide, only 1.52 million were under the age of 20. This surge is largely due to genetic predisposition, environmental factors, and changes in lifestyle patterns.

Technological advancements in diabetes management are anticipated to positively impact market growth. Innovations such as continuous glucose monitors (CGMs), insulin pumps, and artificial pancreas systems enable better glucose control, reducing the risk of complications. For example, in June 2023, the U.S. FDA approved Synjardy (a combination of metformin hydrochloride and empagliflozin) and Jardiance (empagliflozin) for use in children aged 10 and older with type 2 diabetic (T2D), as an adjunct to diet and exercise for better blood sugar control. This approval is expected to significantly enhance treatment options for pediatric with T2D, encouraging broader adoption of these medications in clinical practice. It marks a critical step in expanding access to effective therapies for younger patients, leading to improved disease management and better long-term health outcomes.

Furthermore, the growing awareness and early diagnosis of disease in children have led to an increase in the adoption of various treatment options, including insulin therapies, biguanides, GLP-1 receptor agonists, and SGLT2 inhibitors. The market is also driven by supportive government initiatives and policies aimed at improving access to diabetic care for children. As the global children population continues to rise, along with the increasing prevalence of diabetes, the demand for diabetic treatment is expected to grow significantly during the forecast period.

Pediatric Diabetes Therapeutic Market Report Highlights:

• The type 1 segment held the largest revenue share of 79.32% in 2023. This can be attributed to the increasing incidence and prevalence of type 1 disease and high demand for new therapy treatment across worldwide.
• In treatment, the insulin segment is held the largest share of 35.88% of the market in 2023. This can be attributed to the development and commercialization of novel delivery systems to deliver insulin safely and effectively to children's patients without harm.
• In route of administration, the parenteral segment is held the largest share of 62.50% of the market in 2023. This can be attributed to the growing approval of new subcutaneous and intravenous medicine for treatment of pediatric diabetes patient.
• In distribution channel, the retail pharmacies segment is held the largest share of 47.49% of the market in 2023. This can be attributed to its advantages such as easy accessibility and availability of medication to refill prescriptions of pediatric patients for diabetes treatment.
• North America dominated the market in 2023 with a share of 41.49%, owing to factors such as advanced healthcare infrastructure, increasing prevalence of diabetic in children, and favorable regulatory and reimbursement for clinical trial and treatment.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Treatment
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution Channel
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product and treatment outlook
  • 2.2.2. Route of administration and distribution channel outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Pediatric diabetes therapeutic market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising incidence of diabetic diseases in children
    • 3.2.1.2. Rising awareness about diabetes
    • 3.2.1.3. Advancement in treatment methodologies
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of treatment
    • 3.2.2.2. Stringent regulations pertaining to drug approval
• 3.3. Pediatric Diabetes Therapeutic Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pipeline Analysis

Chapter 4. Pediatric diabetes therapeutic market: Type Estimates & Trend Analysis

• 4.1. Global Pediatric Diabetes Therapeutic Market: Type Dashboard
• 4.2. Global Pediatric Diabetes Therapeutic Market: Type Movement Analysis
• 4.3. Global Pediatric Diabetes Therapeutic Market By Type, Revenue (USD Million)
• 4.4. Type 1
  • 4.4.1. Type 1 market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Type 2
  • 4.5.1. Type 2 market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Pediatric diabetes therapeutic market: Treatment Estimates & Trend Analysis

• 5.1. Global Pediatric Diabetes Therapeutic Market: Treatment Dashboard
• 5.2. Global Pediatric Diabetes Therapeutic Market: Treatment Movement Analysis
• 5.3. Global Pediatric Diabetes Therapeutic Market Estimates and Forecasts, By Treatment, Revenue (USD Million)
• 5.4. Insulin
  • 5.4.1. Insulin market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. GLP-1 Receptor Agonists
  • 5.5.1. GLP-1 Receptor Agonists market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Biguanide
  • 5.6.1. Biguanide market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. SGLT2 Inhibitors
• 5.8. SGLT2 Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
• 5.9. Others
  • 5.9.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Pediatric diabetes therapeutic market: Route of Administration Estimates & Trend Analysis

• 6.1. Global Pediatric Diabetes Therapeutic Market: Route of Administration Dashboard
• 6.2. Global Pediatric Diabetes Therapeutic Market: Route of Administration Movement Analysis
• 6.3. Global Pediatric Diabetes Therapeutic Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
• 6.4. Oral
  • 6.4.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Parenteral
  • 6.5.1. Parenteral market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Pediatric diabetes therapeutic market: Distribution Channel Estimates & Trend Analysis

• 7.1. Global Pediatric Diabetes Therapeutic Market: Distribution Channel Dashboard
• 7.2. Global Pediatric Diabetes Therapeutic Market: Distribution Channel Movement Analysis
• 7.3. Global Pediatric Diabetes Therapeutic Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
• 7.4. Hospital Pharmacies
  • 7.4.1. Hospital Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Retail Pharmacies
  • 7.5.1. Retail pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Online Pharmacies
  • 7.6.1. Online pharmacies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Pediatric diabetes therapeutic market: Regional Estimates & Trend Analysis By Product, Application, and End Use

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. Key company market share analysis, 2023
  • 9.3.2. Boehringer Ingelheim International GmbH.
    • 9.3.2.1. Company overview
    • 9.3.2.2. Financial performance
    • 9.3.2.3. Product benchmarking
    • 9.3.2.4. Strategic initiatives
  • 9.3.3. Eli Lilly and Company
    • 9.3.3.1. Company overview
    • 9.3.3.2. Financial performance
    • 9.3.3.3. Product benchmarking
    • 9.3.3.4. Strategic initiatives
  • 9.3.4. Sanofi
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Vertex Pharmaceuticals Incorporated
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Novo Nordisk A/S
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. AstraZeneca.
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. MannKind Corporation
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Xeris Pharmaceuticals
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Amphastar Pharmaceuticals, Inc.
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives

관련자료